Effect of lithium salts addition on sintering temperature, cationic ordering and dielectric properties of Ba(Mg 1/3 Ta 2/3 )O 3 ceramic

International audienc

Effect of lithium salts addition on sintering temperature, cationic ordering and dielectric properties of Ba(Mg 1/3 Ta 2/3 )O 3 ceramic

International audienc

Low temperature sintering of B2O3/LiNO3 added BaMg1/3Ta2/3O3 ceramics

International audienc

Low temperature sintering of the binary complex perovskite oxides xBa(Zn1/3Ta2/3)O3+(1−x)Ba(Mg1/3Ta2/3)O3

International audienc

Low temperature sintering of the binary complex perovskite oxides xBa(Zn1/3Ta2/3)O3+(1−x)Ba(Mg1/3Ta2/3)O3

International audienc

Low temperature sintering of B2O3/LiNO3 added BaMg1/3Ta2/3O3 ceramics

International audienc

Is the choice between warfarin and fluindion important for patients?

International audienceno abstrac

First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.

PURPOSE: (18)F-Fluorocholine (FCH) and (11)C-acetate (ACE) PET are widely used for detection of recurrent prostate cancer (PC). We present the first results of a comparative, prospective PET/CT study of both tracers evaluated in the same patients presenting with recurrence and low PSA to compare the diagnostic information provided by the two tracers. METHODS: The study group comprised 23 patients studied for a rising PSA level after radical prostatectomy (RP, 7 patients, PSA ≤ 3 ng/ml), curative radiotherapy (RT, 7 patients, PSA ≤ 5 ng/ml) or RP and salvage RT (9 patients, PSA ≤ 5 ng/ml). Both FCH and ACE PET/CT scans were performed in a random sequence a median of 4 days (range 0 to 11 days) apart. FCH PET/CT was started at injection (307 ± 16 MBq) with a 10-min dynamic acquisition of the prostate bed, followed by a whole-body PET scan and late (45 min) imaging of the pelvis. ACE PET/CT was performed as a double whole-body PET scan starting 5 and 22 min after injection (994 ± 72 MBq), and a late view (45 min) of the prostate bed. PET/CT scans were blindly reviewed by two independent pairs of two experienced nuclear medicine physicians, discordant subgroup results being discussed to reach a consensus for positive, negative end equivocal results. RESULTS: PET results were concordant in 88 out of 92 local, regional and distant findings (Cohen's kappa 0.929). In particular, results were concordant in all patients concerning local status, bone metastases and distant findings. Lymph-node results were concordant in 19 patients and different in 4 patients. On a per-patient basis results were concordant in 22 of 23 patients (14 positive, 5 negative and 3 equivocal). In only one patient was ACE PET/CT positive for nodal metastases while FCH PET/CT was overall negative; interestingly, the ACE-positive and FCH-negative lymph nodes became positive in a second FCH PET/CT scan performed a few months later. CONCLUSION: Overall, ACE and FCH PET/CT showed excellent concordance, on both a per-lesion and a per-patient basis, suggesting that both tracers perform equally for recurrent prostate cancer staging